|
Market Closed -
Deutsche Boerse AG
09:11:11 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 22.03 EUR | +1.66% |
|
+1.38% | +4.90% |
| 08-19 | GSK plc : Deutsche Bank remains Neutral | ZD |
| 08-17 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 76,774 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 4.88% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 95,975 | 93,147 | 90,100 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 9.49% | -2.95% | -3.27% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 14.5x | 11.9x | 11.1x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | - | 4.66x | 4.04x | 3.53x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -2.32x | 0.5x | 1.6x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.26x | 2.16x | 2.09x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.83x | 2.62x | 2.46x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.37x | 7.58x | 7.08x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.32x | 8.41x | 7.8x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 17.3x | 16.1x | 13.3x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.78% | 6.22% | 7.54% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6958 | 0.7495 | 0.7831 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.63% | 3.91% | 4.09% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.323 | 1.616 | 1.728 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 52.6% | 46.4% | 45.3% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,942 | 35,540 | 36,692 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,467 | 12,286 | 12,727 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,301 | 11,074 | 11,551 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,436 | 6,484 | 6,933 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 19,200 | 16,373 | 13,325 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 19.16 | 19.16 | 19.16 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,007,011 | - | - |
| Announcement Date | 2/9/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.07x | 12.64x | 25.79x | 0.56% | 1,093B | ||
| 30.16x | - | - | 1.98% | 653B | ||
| 33.05x | 7.66x | 15.93x | 2.65% | 458B | ||
| 20.11x | 4.77x | 11.83x | 2.77% | 355B | ||
| 21.93x | 5.66x | 14.07x | 2.83% | 294B | ||
| 20.48x | 4.23x | 12x | 2.08% | 248B | ||
| 26.9x | 6.98x | 12.39x | 2.37% | 230B | ||
| 13.48x | 4.8x | 10.06x | 3.81% | 203B | ||
| -43.83x | 6.34x | 24.76x | 2.3% | 178B | ||
| Average | 17.48x | 6.63x | 15.85x | 2.37% | 412.27B | |
| Weighted average by Cap. | 25.04x | 8.32x | 18.34x | 1.93% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
















